Eric A Ward, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1022 Winding Wood Trl, Scurry, TX 75158 Phone: 469-744-5765 |
Michelle Blake, LPC ASSOCIATE Counselor Medicare: Not Enrolled in Medicare Practice Location: 9594 S State Highway 34, Scurry, TX 75158 Phone: 469-212-5552 |
Sandra Lynn Starnes Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 12209 Wylie Ln, Scurry, TX 75158 Phone: 888-620-6730 Fax: 972-452-2210 |
Mr. J. Kyle Daniel, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 6950 Shady Ln, Scurry, TX 75158 Phone: 469-721-6621 |
Kynan Kinley, M.A., LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 6950 Shady Ln, Scurry, TX 75158 Phone: 972-452-2210 |
Mr. Randall Eugene Kitchen, LPC, LCDC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 6950 Shady Ln, Scurry, TX 75158 Phone: 972-452-2210 |
News Archive
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.
A new drug called repinotan blocks the respiratory depressant effects of morphine-like opioid drugs—without altering their potent pain-relieving effects, according to a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Vaccine skepticism among young adults may stall efforts to achieve herd immunity - a threshold in which approximately 80 percent of a population is vaccinated against the coronavirus.
AvidBiotics Corp. and Ecolab Inc. today announced an agreement under which they will work to develop a new technology to dramatically reduce the presence of the dangerous pathogen E. coli O157:H7 in red meat products.
New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.
› Verified 4 days ago